Healthcare Equipment and Supplies
Company Overview of EKOS Corporation
EKOS Corporation engages in development and clinical application of ultrasound accelerated thrombolysis system for the treatment of vascular thrombosis. The company offers EkoSonic endovascular system for the controlled and selective infusion of physician-specified fluids, including thrombolytics into the peripheral vasculature. Its ultrasonic devices accelerate the penetration of thrombolytic agents into thrombus, providing high levels of lysis performance and safety in a fraction of the time required by standard catheter-directed thrombolysis. EKOS Corporation serves interventional radiologists, cardiologists, and cardiothoracic and vascular surgeons worldwide. The company was founded in 1...
11911 North Creek Parkway South
Bothell, WA 98011
Founded in 1995
Key Executives for EKOS Corporation
Vice President and General Manager
Vice President of Regulatory & Clinical Affairs
Vice President of Systems Integration
Vice President of Operations
Compensation as of Fiscal Year 2014.
EKOS Corporation Key Developments
EKOS Corporation Initiates a Pivotal New Study in Patients with Chronic Deep Vein Thrombosis and Post-Thrombotic Syndrome
Jun 11 14
EKOS Corporation announced the start of patient enrollment for the ACCelerated ThrombolySiS for Post-Thrombotic Syndrome using the EKOS(R) System (ACCESS PTS) Study. The ACCESS PTS study is a prospective, single-arm, multi-center trial, designed to evaluate the safety and efficacy of ultrasound accelerated thrombolysis using the EkoSonic(R) Endovascular System with standard infusion of a thrombolytic drug for PTS and chronic venous occlusions. The study will enroll up to 200 subjects over a period of 12 months at approximately 30 study sites across the United States. Subjects will receive clinical follow-up for 12 months. Clinical effectiveness will be evaluated using the Villalta score (measurement of the severity of PTS) at baseline compared to 30 days post-EkoSonic(R) treatment. Success will be defined by 50% or more of the subjects achieving at least a 4 point reduction in the Villalta score, which represents a significant improvement in the symptoms of PTS. Potential study subjects will be between 18 and 75 years of age with lower extremity DVT who have: Been objectively diagnosed via imaging as having persistent DVT for at least 6 months. A Villalta score >=8. Failed 3 months of conservative treatment including compression stockings and anticoagulation drugs.
EkoSonic Endovascular System Receives FDA Clearance for the Treatment of Pulmonary Embolism in the USA
May 23 14
EKOS Corporation announced that the U.S. Food and Drug Administration has cleared the EkoSonic Endovascular System for the ultrasound facilitated, controlled and selective infusion of physician-specified fluids, including thrombolytics, into the vasculature for the treatment of pulmonary embolism. The EKOS ultrasonic devices are designed to gently accelerate the penetration of thrombolytic agents into thrombus, providing high levels of lysis. EKOS is the only minimally invasive endovascular therapy on the market that has been FDA cleared for the treatment of PE.
EKOS Corporation Announces U.S. Enrollment Completion of the SEATTLE II Trial that Studies the Safety and Efficacy of Ultrasound Accelerated Thrombolysis for Treatment of Massive and Submassive Pulmonary Embolism
Mar 20 13
EKOS Corporation announced the completion of their second major trial for the treatment of pulmonary embolism (PE). The SEATTLE II study is a 150 patient single arm prospective study measuring the rapid reduction in right heart strain in a patient population with both massive and submassive PE. Up to this point, the current standard of care has been anticoagulation or in the most serious cases intravenous (IV) clot dissolving drugs called thrombolytics. Anticoagulation therapy does not dissolve clots, but rather helps prevent further clots from forming. IV thrombolytics do help dissolve clot but the high dosage required causes serious bleeding in as many as 20% of patients and causes the most feared and devastating bleeding complication, hemorrhagic stroke, in 1% to 3% of patients. Samuel Z. Goldhaber, MD, Professor of Medicine, Harvard Medical School and Director, Venous Thromboembolism Research Group, Brigham and Woman's Hospital (Boston, MA), serves as principal investigator for SEATTLE II. Goldhaber is one of the foremost authorities in the area of PE treatment and has published hundreds of peer-reviewed articles on the subject. Thrombolysis can prevent death and hemodynamic collapse in patients with PE. Goldhaber points out, the challenge has been to minimize the major bleeding complication of intracranial hemorrhage which occurs 10 times more often with IV administered thrombolysis than with heparin alone. It is no surprise that the company, utilizing less than one-fourth of the standard thrombolytic dose, shows a much improved safety record compared with traditional therapy.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|